Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis)

NCT07393217 · tracked via the Priya Life Science Egypt tracker

Sponsor

Sohag University

Phase

Observational

Started

2026-03-01

Last updated

2026-02-06

Condition(s) studied

Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)

Study summary

This study aims to measure a blood protein called fibroblast activation protein (FAP), which is linked to tissue scarring and inflammation. A small blood sample will be taken from participants (RA , SSc patients and healthy people ), and the FAP level will be measured and compared with routine clinical examinations, imaging studies, and lung function tests.

The purpose of this study is to improve understanding of disease activity and lung involvement in these conditions and to explore whether FAP could be useful as a blood marker for future patients. Participation in this study will not change the participant's usual medical care.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Age ≥18 years. Confirmed diagnosis of RA (ACR/EULAR) or SSc (ACR/EULAR). * Ability and willingness to provide informed consent. Cooperative patient able to answer questions. Exclusion Criteria: * Patients under 18 years' old * Active cancer or history of cancer within 5 years. * Other major fibrotic systemic disease that could confound circulating FAP levels. * Acute infection at time of sampling. * Pregnancy or breastfeeding. * Other autoimmune diseases

Primary outcome measure(s)

Serum fibroblast activation protein (FAP) concentration measured by ELISA in patients with rheumatoid arthritis and systemic sclerosis — At baseline (Day 1)

Trial sites (1)

Facility	City	Region	Status
Sohag University Hospital	Sohag	Egypt

More Sohag University trials in Egypt

Peripheral Artery Disease in Regular Hemodialysis Patients Active, not recruiting

the Role of MRI in Evaluation of Low Back Pain Recruiting

Study of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults With Type 1 Diabetes Starting soon

Road Mapping Guided Puncture Versus Ultrasound Guided Puncture During Retrograde Angioplasty Feasibility and Safety Recruiting

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura Recruiting

Other trials for the same condition

The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate Starting soon

Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate Starting soon

Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis Recruiting

Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis Recruiting

"Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease" Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07393217 on ClinicalTrials.gov ↗ ← All trials in Egypt